XAIRA
Live / Applied — First extension granted (statement of use) (as of 06 Jan 2026)
What this means for you
Not registered yet, but its 29 Mar 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98476104
- Mark type
- Stylized text
- Filed
- 29 Mar 2024
- Published for opposition
- 13 May 2025
- Attorney of record
- Trevor A. Caudle, Esq.
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical therapeutics and medical therapeutics for treating indications and co-morbidities underlying immune-mediated inflammatory diseases, namely, pharmaceutical preparations for treating immunological diseases, cardiometabolic diseases, infectious diseases, and oncological diseases
- Class 042 — Scientific and technological services: Pharmaceutical research and development services using artificial intelligence and machine learning; Scientific and medical research in the field of pharmaceutical development using artificial intelligence and machine learning; Research and development of technology in the field of pharmaceuticals; Development of pharmaceutical medicines; Drug development and discovery
Owner
- XAIRA THERAPEUTICS, INC., SAN FRANCISCO, CA, US
- XAIRA THERAPEUTICS, INC., SAN FRANCISCO, CA, US
- Orion Medicines, Inc., San Francisco, CA, US
Prosecution history
- 07 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 06 Jan 2026 — SOU EXTENSION 1 GRANTED
- 06 Jan 2026 — SOU EXTENSION 1 FILED
- 06 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 08 Jul 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 13 May 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 13 May 2025 — PUBLISHED FOR OPPOSITION
- 07 May 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 09 Apr 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 09 Apr 2025 — ATTORNEY REVIEW COMPLETED
- 03 Mar 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 21 Feb 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 03 Mar 2025 — ASSIGNED TO LIE
- 21 Feb 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 19 Feb 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED